This study is about testing two medicines, **zibotentan** and **dapagliflozin**, for people with a kidney problem called **chronic kidney disease (CKD)**. CKD means the kidneys don’t work as well as they should. Some people with CKD have **high proteinuria**, which means there is too much protein in their urine, a sign of kidney damage. The study is called **ZENITH High Proteinuria**. It is a Phase III study, meaning it's in the late stages of research to check how well the medicines work, if they are safe, and if people can handle taking them. Participants are randomly chosen to get either both zibotentan/dapagliflozin or just dapagliflozin, but neither they nor the doctors know who gets which (this is called double-blinded).

• Participants need to be 18 or older and have CKD with specific protein levels in their urine and kidney function (eGFR) between 20 and 90.
• People with certain heart problems, some cancers, or other serious health issues cannot join.
• Participants should already be on a stable dose of RAASi therapy, a common treatment for CKD.